



Study Title:	Treatment Trial for Previously Treated Prostate Cancer
Scientific Title:	ECOG E2809: Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Department and/or Specialty:	RCC Research
Investigator:	Michael Thompson, MD, PhD
Contact Information:	Chanda Miller 262-928-5539
<p>Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether bicalutamide is more effective with or without MK2206 in treating prostate cancer.</p> <p>This phase II clinical trial is studying how well giving bicalutamide with or without MK2206 works in treating patients with previously treated prostate cancer.</p>	



PROHEALTH CARE
RESEARCH INSTITUTE